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Abstract 
A simple and reliable new HPLC method with UV detection has been developed and 
validated for simultaneous determination of mitotane and its two metabolites DDA and 
DDE. Method development was carried out utilizing systematical approach of the Design 
of Experiments (DoE) methodology. For estimation of factors influence on selected 
chromatographic responses and definition of the optimal chromatographic conditions, 
Box-Behnken experimental design was applied. The defined optimal separation 
conditions were: column Restek Ultra Aqua C18 with pre-column Restek Ultra Aqua C18 
operating at temperature 35 C; mixture of acetonitrile and 0.5% formic acid as mobile 
phase with 1.2 mL min
−1
 flow rate and detection at 230 nm. As sample preparation 
method, liquid-liquid extraction was chosen. Method was fully validated and LOQ and 
LOD were experimentally determined. Finally, method was successfully applied for 
determination of mitotane and its metabolites in plasma samples of patients with 
adrenocortical carcinoma. 
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INTRODUCTION 
Determination of drug and its metabolites in biological samples often presents a 
challenge. Knowing complexity of biological samples, assay of low levels of drug and its 
metabolites demands systematic approach. As many steps are included in such kind of 
investigation, every step should be carefully conducted in order to achieve the most 
suitable method. In this study, systematic approach including the Design of Experiments 
(DoE) methodology for a development of a new liquid chromatographic method (LC) for 
the analysis of mitotane and its metabolites (DDA – 1,1-(o,p'-dichlorodiphenyl) acetic 
acid and DDE–1,1-(o,p'-dichlorodiphenyl)-2,2 dichloroethene) in human plasma was 
applied.  
 
Mitotane, chemically 1,1-(o,p’-dichlorodiphenyl)-2,2-dichloroethane, (o,p’- DDD) is 
used for the therapy of adrenocortical carcinoma (ACC) for the last 50 years. ACC is a 
rare, highly malignant neoplasm with an incidence of 2 cases per million people per year 
worldwide, with only 16% to 38% of patients surviving for more than 5 years after 
diagnosis 1-3 . Even after surgical resection of tumor, local or metastatic recurrence is 
frequent and 75% to 85% of patients have relapse after radical resection 4, 5 . This high 
recurrence rate, incompletely understood pathogenesis and poor prognosis of disease 
forced investigators to consider the use of adjuvant therapy - mitotane has been widely 
used for this purpose. Adjuvant mitotane may prolong recurrence-free survival in patients 
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with radically resected ACC 6 . Unfortunately, the exact mitotane adrenocorticolytic 
mechanism of action is unknown. After intake, mitotane undergoes biotransformation in 
liver and other tissues to two main metabolites – DDA and DDE catalyzed by a P-450 
enzyme following α- and β- hydroxylation, respectively. β- Hydroxylation is transformed 
by dehydrochlorination into an acyl chloride which either covalently binds to 
bionucleophiles in the cancer cells or is transformed to an acetic acid derivate (DDA) for 
renal excretion (Figure 1). Mitotane and its metabolites are presented in Figure 2.  
 
Careful monitoring of plasma mitotane concentrations is very important because of the 
narrow therapeutic window lying between 14 g mL
−1 
and 20 g mL
−1
. Mitotane plasma 
levels above 14 g mL
−1
are required for therapeutic effects, whereas plasma 
concentrations higher than 20 g mL
−1
correlate with significant side effects, especially 
neurological toxicity. About 40% of patients suffer some central toxicity with dizziness, 
vertigo, sedation, lethargy and depression. Next to these side effects, most of the patients 
receiving mitotane have anorexia, nausea, vomiting and sometimes diarrhea. Due to its 
lipophilicity, mitotane accumulates in adipose tissue, so the plasma half-life is extremely 
long (18-159 days). Consequently, it can take months to reach the steady state 7 . The 
maximum tolerated oral dosage of mitotane range from about 2 g to 16 g (usually 6-10 g) 
per day 8 . 
 
The monitoring of plasma levels of mitotane and its metabolite is required in order to 
balance the good therapeutic efficacy with the acceptable toxicity. Literature survey 
shows that there are only few papers dealing with determination of mitotane and its 
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metabolites in plasma 9–11 . In papers 9, 10  gradient elution mode was employed 
while in 11  isocratic mode was used. In all three published methods UV detection was 
utilized 9–11 . In previously published studies, a simple trial and error approach was 
used in method development. In this paper, a strategy which included DoE methodology 
was employed in the development of new LC method for the analysis of mitotane and its 
metabolites in plasma samples. The application of DoE methodology in LC method 
development provides a detailed view of the analyzed system and enables a mathematical 
description of the system behavior, after performing a minimal number of well-planned 
experiments. Following this strategy, a improvement of LC method for mitotane and its 
metabolite analysis was achieved and, consequently, optimal chromatographic conditions 
were successfully defined. Finally, the method was fully validated and applied for the 
determination of mitotane and its metabolites in patients’ plasma samples.  
 
EXPERIMENTAL 
Reagents and Standard Substances 
Mitotane, p,p’-DDA, p,p’-DDE and DDT – dichlorodiphenyltrichloroethane (internal 
standard) and formic acid were purchased from Sigma-Aldrich, Germany. Acetonitrile 
was obtained from J. T. Baker, The Netherlands and HPLC grade ethanol from Fischer 
Scientific, U. K. 
 
Stock Solutions 
All stock standard solutions of the studied compounds and internal standard were 
prepared in ethanol HPLC grade at the concentration of 0.5 mg mL
−1
. 
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Chromatographic Conditions 
The chromatographic system Spectra System consisting of Spectra P1000 HPLC Pump, 
Spectra AS3000 autosampler, Spectra UV1000 UV absorbance detector and Chromeleon 
Client Program (Software Windows XP) was used for data collection. Separations were 
performed on a Restek Ultra Aqua C18, (30 mm  4.6 mm, 3 m particle size) with pre-
column Restek Ultra Aqua C18 (10 mm 4.6 mm, 3 m particle size), temperature at 35° 
C with UV detection at 230 nm and mobile phase flow rate 1.2 mL min
−1
. Injection 
volume was 50 L.  
 
Mobile phases were prepared by mixing water phase (water and formic acid) with 
acetonitrile. Final content of mobile phase as well as its final column temperature were 
defined during the method optimization. 
 
METHODS OPTIMIZATION 
Solutions for Method Optimization 
For method optimization the stock solutions of mitotane, DDA and DDE were used to 
prepare a mixture with concentration of 60 g mL
−1
 for mitotane, DDA and DDE in 
ethanol HPLC grade. 
 
Experimental Procedure 
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Experiments were done according to the matrix of experiments created by Box-Behnken 
design. All factors were investigated in three levels (−1, 0 and +1). Factors, their levels in 
real and coded values are given in Table 1. 
 
Software  
Experimental design and data analysis were performed using Design−Expert® 7.0.0. 
(Stat−Ease Inc., Minneapolis).  
 
SAMPLE PREPARATION 
400 μL thawed plasma samples were spiked with 200 μL of the internal standard DDT 
(0.05 mg mL
−1
 in ethanol) in microcentrifuge tubes and vortexed well. Plasma standards 
and patient samples were treated in the same way. Proteins were precipitated by adding 
500 μL of cold HPLC quality ethanol, followed by vortex mixing and centrifugation at 
14000 x g at 4 °C for 10 minutes in the Universal 32R (Hettich-Zentrifugen). After 
transferring supernatant into a new microcentrifuge tube, 100 μL of 0.5% formic acid was 
added, vortexed and centrifuged again at 14000 x g at 4 °C for 10 minutes. The final 
supernatant was transferred into autosampler tubes of HPLC and 50 μL was injected. In 
case when measured peaks were out of calibration curve, appropriate dilutions were made. 
 
Patient Blood Sample Preparation 
Patients were informed about the purpose of the study and provided written informed 
consent before the enrolment. Mitotane dosage regimens were in the range from 3 to 12 g, 
three times per day. Patient blood samples were collected in a 5 mL potassium - 
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ethylenediamine tetraacetate (K-EDTA) tubes 8 h after the consumption of the last 
mitotane daily dose. The plasma was separated using the centrifugation and the samples 
were stored at −80 °C until assayed. 
 
METHOD S VALIDATION 
Solutions for Specificity Testing 
In order to prove specificity of the method 400 μL of blank plasma was spiked with 200 
μL of mixture containing 60 g mL−1 of mitotane, DDA, DDE and 0.05 mg mL−1 of DDT 
followed by the above described extraction procedure. Obtained chromatogram was 
compared to chromatogram of the blank plasma.  
 
Solutions for Linearity Testing 
For the linearity testing of mitotane, DDA and DDE a stock standard solution of 0.5 mg 
mL
−1
 of each compound (prepared in HPLC grade ethanol) was used. The first nine 
working standard solutions with following concentrations 2.5, 5, 15, 30, 45, 60, 90, 120 
and 150 g mL
−1
 of each substance were prepared. Additionally, standard solution of 5 
mg mL
−1
 of DDA was used to prepare additional five standard solutions at concentrations 
of 300, 450, 600, 900 and 1200 g mL
−1. Aliquots of 200 μL of analyte standard 
solutions were added to 400 μL of blank plasma, followed by above described extraction 
procedure. Internal standard (DDT) was added in all standard solutions in the 
concentration of 0.05 mg mL
−1
. Calibration curves and equations were obtained using 
least-squares linear regression analysis of the peak area (AUC) vs analyte concentrations.  
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Extraction Efficiency Testing 
Extraction efficiency of mitotane and its metabolites was determined by adding 200 μL of 
working standard solutions at four different concentrations (5, 45, 120 and 600 g mL
−1
 – 
QC samples) – DDA and three different concentration (5, 45 and 120 g mL−1 – QC 
samples) – for mitotane and DDE to the 400 μL of blank plasma, followed by described 
extraction and repeating the whole procedure three times. The HPLC – derived peak 
areas obtained were compared with those obtained from standard solutions at the same 
four concentrations, six times diluted and injected directly into the liquid 
chromatographic apparatus. The percentage of the extraction yield was calculated and 
presented as Recovery value. 
 
Accuracy Testing 
The accuracy of the method was determined in four different concentrations (5, 45, 120 
and 600 g mL
−1
 – QC samples) for DDA and three different concentrations (5, 45 and 
120 g mL
−1
 – QC samples) for mitotane and DDE. Aliquots of 200 μL of working 
standard solutions in these mentioned concentrations were added to 400 μL of blank 
plasma and extracted as described. The procedure was repeated three times at each 
concentration level and the accuracy of the measurements was expressed in terms of 
Recovery. 
 
Precision Testing 
The precision experiments for mitotane, DDA and DDE were performed by spiking 400 
μL of blank plasma with 200 μL of working standard solution of the QC samples, 
D
ow
nl
oa
de
d 
by
 [U
Q 
Li
bra
ry]
 at
 01
:05
 21
 Ju
ne
 20
15
 
  9 
followed by extraction. The procedure was repeated six times within the same day to 
obtain intra-day precision and the inter-day precision was assessed by replicate analysis 
on the second and the third day. The results of the precision measurements were 
expressed as relative standard deviation (RSD) values.  
 
Freeze and Thaw Stability Testing 
Six thawed blank plasma samples were spiked with 200 μL of working standard solution 
of the QC samples
 
for mitotane, DDA and DDE, vortexed well and frozen at −80°C for 
30 days in order to test stability of studied substances. Three sets of these samples were 
prepared. After 30 days all sets of samples were thawed at the room temperature and first 
set of samples were extracted and injected in HPLC system, while the other two sets are 
returned and stored again at −80 °C. The freeze/thaw cycle followed by extraction 
procedure was repeated for remaining two sets of samples after another 30 (60) days. 
 
RESULTS AND DISCUSSION 
Method Development 
In order to achieve the most suitable performance in chromatographic method it is 
necessary to apply the systematic approach. In the beginning, this approach demands 
understanding of nature and chemical characteristics of investigated substance in order to 
establish relationship between its properties and chromatographic conditions. This is 
important in order to define desirable characteristics of chromatogram at the start.  
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So, we began primarily with some general consideration. Taking into account that 
mitotane and its metabolites are highly lipophilic non-polar compounds, the reversed 
phase chromatography mode should be the best choice. High dose of mitotane used in 
therapy and previously published studies led to conclusion that UV detector has quite 
enough sensitivity for this analysis. In line with the reference 11 , wavelength of 230 nm 
was chosen. Further, according to previously published papers, where mitotane and its 
metabolites were investigated chromatographically 9–11 , early eluting substance was 
DDA because of the presence of carboxylic group while the last eluted substance was 
DDE. De Francia et al. (9) in the paper, applied two separate gradient methods in order to 
solve this challenge. In the remaining papers 10, 11  isocratic elution was applied, but 
DDA was eluted very near to the mobile phase peak. According to these findings as well 
as characteristics of the sample, as the first desired characteristic of chromatogram in 
present study, the retention factor for DDA was defined to be not less than 3.0. The other 
two substances are more lipophilic and, in order to avoid their long elution, short 
octadecyl column was selected. Based on these considerations, the second important 
characteristic of chromatogram is the retention time of the last eluting substance acting as 
an indicator of the overall run time. Finally, as a last parameter of the chromatogram´s 
quality, the resolution between last eluted substances was set at 1.5. After the analysis of 
already existing data and defining the quality of desirable chromatogram, preliminary 
experiments were conducted. 
 
Based on the chemical structure of investigated substances, especially acid character of 
DDA, mobile phase with acidic pH was selected. As an organic modifier in mobile phase, 
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acetonitrile was chosen. Taking into account previously discussed considerations, 
scouting experiments on short C18 columns (Restek Ultra Aqua C18 (30 mm  4.6 mm, 3 
m particle size) and XTerra
®
 C18 (20 mm  4.6 mm, 3.5 m particle size column)) were 
done. In these experiments the content of acetonitrile varied from 40% to 80%. 
Simultaneously, different water phase was used – various additives were used for pH 
adjustment (glacial acetic acid, phosphoric acid and formic acid). In line with the 
previously defined desirable characteristics of chromatogram and based on the scouting 
experiments, Restek Ultra Aqua C18 (30 mm  4.6 mm, 3 m particle size) was chosen. 
Further on, about 50% of acetonitrile was selected as acceptable, with formic acid in 
water phase. Flow rate was varied from 1.0 mL min
−1
 to 1.5 mL min
−1
, where 1.2 mL 
min
−1
 was set as final flow rate. 
 
Based on the preliminary experiments, some frameworks of chromatographic conditions 
were defined (e. g. column type, flow rate and organic modifier) but other factors 
(acetonitrile content, content of formic acid and column temperature) were to be 
optimized. In order to choose optimal chromatographic conditions and investigate 
behavior of substances in certain experimental space, DoE methodology was chosen. 
Successful application of this methodology in LC method optimization was published in 
many papers such as 12–17 .  
 
In this study, from preliminary experiments three factors were selected to be changed 
during the optimization: content of acetonitrile in mobile phase, content of formic acid in 
water phase and column temperature. Factors and their levels are presented in Table 1. 
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Other chromatographic factors (flow rate and wavelength kept on the constant level 
during optimization). 
 
For the optimization, Box-Behnken design (BBD) as a kind of response surface design 
was chosen. BBD is based on three–level incomplete factorial designs where two factors 
are arranged in a full two–level design, while the level of the third factor is set at zero 
12 . If three factors are to be examined, twelve experiments plus central point 
replications are required. Also, BBD is nearly rotatable and especially useful when the 
points on one or more corners of the cube represent factor–level combinations 
unacceptably expensive or impossible to carry out due to physical constraints of the 
experimentation 18 . 
 
As the responses, previously defined important characteristics of chromatogram 
(retention factor of DDA, retention time of DDE and resolution between DDE and 
mitotane) were followed and the obtained results are given in Table 1. 
Further, the results were statistically evaluated. The obtained values for coefficients and 
important statistical data are given in Table 2. 
 
Table 3 presents coefficients for coded factor levels with corresponding p–values. Also, 
coefficients of determination (R
2
) and adjusted values of the coefficients of determination 
(adj. R
2
) are given. All the obtained models had high values of R
2
 (> 0.98) and adj. R
2
 (> 
0.95), which revealed that experimental data fitted well in the second–order polynomial 
equations. Also, values for predicted R
2
 is higher than 0.80 which confirmed that 
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obtained models have good predictive ability. For all tested models lack of fit value was 
not significant. Next to that, values for p were analyzed and values greater than 0.1000 
indicate that model terms are significant. Acetonitrile is a factor with the strongest 
influence on all followed responses (value p is lower than 0.1000). In addition, in all 
three created models the coefficients corresponding to acetonitrile (b1) had minus sign, 
which means that higher values of acetonitrile influence the decrease of all three analyzed 
responses. Additionally, p value for coefficient b23 (interaction of formic acid content and 
temperature) for all followed responses was considered significant. The third followed 
response (R) is under the strong influence of acetonitrile, column temperature and the 
interactions acetonitrile – formic acid content (b12) and content of formic acid – 
temperature (b23). Besides these significant influences, resolution factor in all 
experiments had adequate values leading to conclusion that in all investigated 
experimental space proper separation was achieved.  
 
In order to define optimal region overlay plot was constructed. Desirable values for 
investigated responses was set, for k1 maximal values, for t3 values lower than 16 minutes 
while value for R was set in range presented in Table 2. Column temperature was set at 
nominal value (35 C) and obtained overlay plot is presented in Figure 3. 
 
Yellow part of graph presented range of factors whose gives desirable responses. From 
this region we choose 53% of acetonitrile in mobile phase and 0.5% of formic acid as 
optimal values. Under chosen experimental conditions, all previously defined goals of the 
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method optimization were achieved with optimal run times, optimal resolution and 
retention of DDA.  
 
The presented DoE methodology enables analysis of the chromatographic system in 
defined range of investigated factors. It makes easier to realize the regions with optimal 
as well as desirable responses (Figure 3). In this case, where DoE was applied in the 
development of LC method for mitotane and metabolites determination, all the previously 
defined aims were accomplished. Finally, some significant advantages were achieved in 
comparison to previously published methods. In comparison to paper 9 , where gradient 
elution was applied, this investigation brings the isocratic method. Furthermore, the run 
time in 10
 
 paper was 20 minutes, while in this study the separation is achieved in less 
than 15 minutes. Also, in the presented study, a significantly lower content of acetonitrile 
in the mobile phase was used compared to the previous publications 10, 11 , which is 
considered as a very important environmental toxicity aspect. Generally, the employment 
of DoE strategy enables the improved understanding of the given LC system, thus 
providing an efficient LC method for the analysis of mitotane and its metabolites. 
 
Next, under the optimal chromatographic conditions internal standard was chosen. 
Considering mitotane as a derivate of DDT and taking into account their similar chemical 
structures, DDT was injected under the obtained chromatographic conditions. It was 
confirmed that appropriate separation from other compounds in the mixture was achieved. 
Under the optimal chromatographic conditions chromatograms of the blank plasma and 
plasma spiked with working standards were recorded and presented in Figure 4.  
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For the sample preparation, liquid-liquid extraction was performed. Guideline for sample 
preparation was found in paper published 10 . Procedure was tested in our laboratory 
and feasibility was confirmed. Considering different water phase, final dilution was made 
with water phase consisting of 0.5% formic acid. Details for sample preparation are given 
in Experimental part.  
 
Method S Validation 
Firstly, method specificity was investigated. Under the optimal conditions the solutions 
of the blank plasma and plasma spiked with standards of DDA, DDT, mitotane and DDE 
were injected into HPLC system and chromatograms were recorded. Obtained 
chromatograms are presented in Figure 4. There is no endogenous interference from 
drug-free plasma and the method is selective for determination of above mentioned drug 
and its metabolites in plasma.  
 
As a next important parameter of method validation the linearity of the method was tested. 
Linearity for mitotane and DDE were tested in range from 0.417 g mL
-1 
to 25.0 g mL
-1
 
and for DDA in range from 0.417 g mL
-1 
to 200.0 g mL
-1
. The calibration curve was 
linear over the studied concentration range (R
2
 >0.9968) for all investigated compounds. 
The obtained results for linearity testing are presented in Table 3. 
 
 LOQ and LOD were experimentally determined and obtained values for LOQ 
were 0.4 g mL
−1
 for mitotane, DDA and DDE and LOD was 0.2 g mL
−1
 for mitotane 
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and DDA and g mL
−1
 for DDE. Obtained values for LOD and LOQ were in agreement 
with the previously published confirming the adequate sensitivity of method for the 
analysis of mitotane, DDA and DDE metabolites. 
 
Further, the extraction efficiency was evaluated according to the procedure given in 
Experimental part. Range of the obtained Recovery values for investigated substances 
were 96.09% – 101.32%, 99.37% – 102.08% and 98.02%–99.75% for DDA, mitotane 
and DDE, respectively. It should be pointed out that adequate extraction efficiency was 
achieved. 
 
Accuracy of the presented chromatographic method was determined in four different 
levels for DDA and in three different levels for mitotane and DDE (see Experimental part 
for procedure). Results are shown in Table 3. Obtained results for Recovery values 
confirmed good accuracy of the method.  
 
 The results of the precision experiments were expressed as the relative standard 
deviation (RSD) and the obtained values were 1.77%, 3.38% and 0.85% for mitotane, 
DDA and DDE, respectively. At the same concentration levels freeze and thaw stability 
was checked (see Experimental part for procedure) and obtained results for RSD (the 
highest value was 0.6%) confirm adequate stability of the samples. 
 
Patient Samples 
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The optimized and validated LC method was used to determine plasma levels of mitotane 
and its metabolites in plasma samples of 6 patients with mitotane doses ranging from 3 to 
12 g per day, taken in three daily doses. Plasma samples were retrieved in the morning, at 
least 6-8 h after administration. Mitotane levels ranged from 6.6 g mL
−1 
to 43.6 g mL
−1
 
and DDA levels from 11.28 g mL
−1 
to 151.47 g mL
−1
. Also, the ratios of 
DDA/mitotane were followed and the obtained values ranged from 1.53-10.59. In the 
analyzed samples DDE level was lower than LOQ. As it is previously mentioned, 
pharmacokinetic characteristics of mitotane are complex because of its lipophilicity and 
consequently very long elimination half-time. In addition, the measurement of patients’ 
mitotane and its metabolites plasma levels show significant variability in metabolism 
between patients indicating how more regular therapeutic drug monitoring may 
contribute to the main goal in therapy – good therapeutic efficacy with acceptable 
toxicity. Finally, the chromatogram of one patient sample is given in Figure 5. 
 
CONCLUSION 
In this study, the development of the new LC method for determination of mitotane and 
its two metabolites in human plasma employing DoE methodology is presented. In order 
to achieve defined aim in method optimization (acceptable retention factor of DDA, 
optimal run time and adequate separation) Box-Behnken design was used. Statistical and 
graphical interpretation of the obtained results enables setting of optimal 
chromatographic conditions where significant improvement of the method was achieved. 
Thereafter, the method was validated and successfully applied for the analysis of plasma 
samples obtained from patients treated with different daily doses of mitotane. 
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Concentration levels of mitotane and metabolite DDA were quantified while level for 
DDE was below limit of quantification.  
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Table 1. Plan of experiments for Box-Benhken design and results obtained for responses 
A B C kDDA tDDE RDDE/mitotan 
51 (−1)* 0.3 (−1) 35 (0) 4.768 18.868 4.944 
55 (+1) 0.3 (−1) 35 (0) 3.561 12.110 4.300 
51 (−1) 0.7 (+1) 35 (0) 4.563 18.600 5.100 
55 (+1) 0.7 (+1) 35 (0) 3.182 11.528 4.079 
51 (−1) 0.5 (0) 30 (−1) 4.861 20.203 5.130 
55 (+1) 0.5 (0) 30 (−1) 3.350 12.228 4.204 
51 (−1) 0.5 (0) 40 (+1) 4.587 18.839 4.950 
55 (+1) 0.5 (0) 40 (+1) 3.048 11.82 3.969 
53 (0) 0.3 (−1) 30 (−1) 4.05 15.052 4.562 
53 (0) 0.7 (+1) 30 (−1) 4.352 16.755 4.831 
53 (0) 0.3 (−1) 40 (+1) 4.287 16.911 4.677 
53 (0) 0.7 (+1) 40 (+1) 3.77 15.039 4.414 
53 (0) 0.5 (0) 35 (0) 3.95 15.705 4.662 
53 (0) 0.5 (0) 35 (0) 4.086 15.465 4.686 
53 (0) 0.5 (0) 35 (0) 4.108 15.836 4.512 
A – concentration of acetonitrile (%); B – concentration of formic acid; C – column 
temperature (°C); 
kDDA – retention factor of DDA; tDDE – retention time for DDE; R – resolution between 
DDE and mitotane  
*in the brackets coded values for factor levels are given 
 
D
ow
nl
oa
de
d 
by
 [U
Q 
Li
bra
ry]
 at
 01
:05
 21
 Ju
ne
 20
15
 
  23 
Table 2. Coefficients of quadratic model y = b0 + b1x1 + b2x2 + b3x3 + b12x1x2 + b13x1x3 + 
b23x2x3 + b11x1
2
 + b22x2
2
 + b33x3
2
 
 k1 t3 R 
 coefficient p-value coefficient p-value coefficient p-value 
b0 4.04  15.65  4.62  
b1 −0.71 <0.0001* −3.60 <0.0001* −0.45 <0.0001* 
b2 −0.100 0.0545 −0.13 0.3928 −0.0074 0.7886 
b3 −0.11 0.0359* −0.20 0.1953 −0.090 0.0186* 
b12 −0.043 0.4801 −0.078 0.7006 −0.094 0.0516* 
b13 −0.0004 0.9477 +0.24 0.2699 −0.014 0.7234 
b23 −0.20 0.0151* −0.89 0.0056* −0.13 0.0158* 
b11 −0.089 0.1897 −0.27 0.2334 −0.036 0.3917 
b22 +0.069 0.2947 −0.11 0.6228 −0.022 0.5932 
b33 +0,0069 0.9109 +0.39 0.1088 −0.021 0.6126 
Lack of 
fit 0.2670 0.1125 0.7930 
R
2
 0.9857 0.9932 0.9848 
adj. R
2
 0.9600 0.9810 0.9575 
Pred. R
2
 0.8083 0.8986 0.8928 
k1 – retention factor of DDA, t3  – retention time of DDE; R – resolution between DDE 
and mitotane 
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Table 3. Results from linearity and accuracy testing 
Substance Linearity Accuracy 
Concentration range 
( g mL
−1
) 
Equation Correlation 
coefficient 
Spiked concentration 
( g mL
−1
) 
Recovery (%) RSD 
(%) 
DDA 0.417 – 200.0  y=0.1746x+0.00836 0.9968 0.833 92.7 5.99 
7.5 88.67 0.89 
20 86.89 0.61 
100 97.2 1.36 
Mitotane 0.417 – 25.0  y=0.1457x−0.06112 0.9979 0.833 102.78 6.12 
7.5 91.67 1.12 
20 91.72 0.45 
DDE 0.417 – 25.0  y=0.165x−0.016 0.9990 0.833 92.97 1.73 
7.5 100.18 0.51 
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20 99.27 0.74 
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Figure 1. Structures of mitotane, its two metabolites (DDA and DDE) and internal 
standard (DDT) 
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Figure 2. Metabolic pathway of mitotane 
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Figure 3. Overlay plot 
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Figure 4. Chromatograms for A. blank plasma, B. plasma spiked with standards of DDA, 
DDT, mitotane and DDE; Chromatographic condition: Column Restek Ultra Aqua C18 
(30 mm  4.6 mm, 3 m particle size) with pre-column Restek Ultra Aqua C18 (10 mm 
4.6 mm, 3 m particle size), with mobile phase consisted of acetonitrile and 0.5% 
formic acid in ratio 53:47 V/V, column temperature 35 C, flow rate 1.2 mL min
-1
, 
wavelength 230 nm and injection volume of 50 L. 
 
 
 
 
 
 
 
 
D
ow
nl
oa
de
d 
by
 [U
Q 
Li
bra
ry]
 at
 01
:05
 21
 Ju
ne
 20
15
 
  30 
Figure 5. Patient sample chromatogram  
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